Fig 1: HH cells abundantly express CD30 and the viability is reduced after BV treatment. a Cell viabilities following treatment with BV (0.0068–68 nM) for 72 h. b Flow cytometry histograms. Cells were sorted following staining with PE-conjugated anti-CD30 antibodies (orange), with isotype-matched control antibodies (blue), or without antibodies (red). BV brentuximab vedotin, PE phycoerythrin